topiramate

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alcoholism

Conditions

Alcoholism

Trial Timeline

Mar 1, 2004 → Aug 1, 2006

NCT ID

NCT00210925

About topiramate

topiramate is a phase 2 stage product being developed by Johnson & Johnson for Alcoholism. The current trial status is completed. This product is registered under clinical trial identifier NCT00210925. Target conditions include Alcoholism.

What happened to similar drugs?

4 of 9 similar drugs in Alcoholism were approved

Approved (4) Terminated (1) Active (4)

✅Seroquel XRAstraZenecaApproved

✅Acamprosate or NaltrexoneMerckApproved

✅Acamprosate + PlaceboMerckApproved

✅LevetiracetamUCBApproved

🔄Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy + Naltrexone 50 mg/day + Cognitive Behavioral Therapy + Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3

❌Medisorb naltrexone 380 mg + Oral naltrexone to Medisorb naltrexone 380 mgAlkermesPhase 3

🔄Medisorb naltrexone 380 mg + Medisorb naltrexone 190 mgAlkermesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00223626	Phase 2	Completed	Jan 1, 2007	Dec 1, 2010	Cocaine-Related Disorders
NCT00266604	Approved	Completed	Dec 1, 2005	Jun 1, 2007	Epilepsy
NCT00223639	Phase 2	Completed	Sep 1, 2005	Jul 1, 2008	Alcoholism
NCT00233012	Phase 1	Completed	Jun 1, 2005	Oct 1, 2007	Seizures
NCT00210574	Phase 2	Completed	Mar 1, 2005	Oct 1, 2006	Epilepsy, Absence
NCT00210860	Phase 3	Completed	Sep 1, 2004	Mar 1, 2006	Migraine
NCT00210925	Phase 2	Completed	Mar 1, 2004	Aug 1, 2006	Alcoholism
NCT00231647	Phase 2	Completed	Feb 1, 2004	Oct 1, 2004	Obesity
NCT00210821	Phase 3	Completed	Feb 1, 2004	Nov 1, 2005	Migraine
NCT00210873	Phase 3	Completed	Feb 1, 2004	Aug 1, 2005	Migraine
NCT00210808	Phase 2/3	Completed	Sep 1, 2003	Mar 1, 2005	Obesity
NCT00210912	Phase 3	Completed	Sep 1, 2003	Apr 1, 2005	Migraine
NCT00236496	Phase 3	Completed	Oct 1, 2001	Feb 1, 2004	Essential Tremor
NCT00035230	Phase 3	Completed	Jul 1, 2001	Nov 1, 2002	Bipolar Disorder
NCT00231673	Phase 2	Completed	Jul 1, 2001	Jan 1, 2003	Diabetic Neuropathies
NCT00231634	Phase 3	Terminated	May 1, 2001	Nov 1, 2002	Obesity
NCT00231621	Phase 3	Terminated	May 1, 2001	Jun 1, 2002	Obesity
NCT00231595	Phase 3	Completed	Mar 1, 2001	Nov 1, 2002	Migraine
NCT00236665	Phase 3	Completed	Mar 1, 2001	Jun 1, 2002	Obesity
NCT00236509	Phase 3	Completed	Feb 1, 2001	Sep 1, 2002	Migraine

Competing Products

18 competing products in Alcoholism

See all competitors

Product	Company	Stage	Hype Score
acamprosate	Johnson & Johnson	Pre-clinical	26
Topiramate and Naltrexone	Johnson & Johnson	Phase 1	29
Topiramate	Johnson & Johnson	Phase 2	35
ondansetron + cognitive behavioral therapy + topiramate + cognitive behavioral therapy + Placebo + cognitive behavioral therapy + ondansetron + topiramate + cognitive behavioral therapy	Johnson & Johnson	Phase 2	31
Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy + Naltrexone 50 mg/day + Cognitive Behavioral Therapy + Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy	Johnson & Johnson	Phase 3	40
Seroquel XR	AstraZeneca	Approved	43
Quetiapine fumarate	AstraZeneca	Phase 2	35
Acamprosate or Naltrexone	Merck	Approved	43
Acamprosate + Placebo	Merck	Approved	43
SCH 900435 + Placebo	Merck	Phase 2	27
CP-866,087	Pfizer	Phase 2	35
Levetiracetam	UCB	Approved	43
levetiracetam	UCB	Phase 2	35
Nalmefene + Placebo	Lundbeck	Phase 1	18
Medisorb naltrexone 380 mg + Oral naltrexone to Medisorb naltrexone 380 mg	Alkermes	Phase 3	29
Medisorb naltrexone 380 mg + Medisorb naltrexone 190 mg	Alkermes	Phase 3	37
Medisorb naltrexone 380 mg + Oral naltrexone 50 mg	Alkermes	Phase 3	37
Medisorb naltrexone 190 mg + Medisorb naltrexone 380 mg + Placebo matching Medisorb naltrexone 190 mg + Placebo matching Medisorb naltrexone 380 mg	Alkermes	Phase 3	37